Pfizer Inc. (NYSE:PFE - Get Free Report) shares rose 0.1% during trading on Thursday . The stock traded as high as $26.08 and last traded at $25.92. Approximately 6,681,545 shares were traded during mid-day trading, a decline of 82% from the average daily volume of 37,093,660 shares. The stock had previously closed at $25.89.
PFE has been the topic of several recent analyst reports. StockNews.com downgraded Pfizer from a "strong-buy" rating to a "buy" rating in a report on Wednesday, November 20th. Citigroup reduced their target price on Pfizer from $30.00 to $29.00 and set a "neutral" rating on the stock in a report on Tuesday, January 28th. Evercore ISI raised Pfizer to a "strong-buy" rating in a report on Wednesday, October 30th. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $45.00 price objective on shares of Pfizer in a report on Wednesday, October 23rd. Finally, Bank of America reaffirmed a "neutral" rating and set a $29.00 price objective on shares of Pfizer in a report on Tuesday, December 10th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, six have assigned a buy rating and two have assigned a strong buy rating to the stock. Based on data from MarketBeat, Pfizer has a consensus rating of "Moderate Buy" and a consensus price target of $31.92.
Get Our Latest Analysis on PFE
The stock has a 50 day moving average price of $26.28 and a two-hundred day moving average price of $27.45. The company has a current ratio of 1.00, a quick ratio of 0.73 and a debt-to-equity ratio of 0.63. The company has a market cap of $146.41 billion, a price-to-earnings ratio of 18.32, a P/E/G ratio of 0.63 and a beta of 0.64.
Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $0.63 EPS for the quarter, beating analysts' consensus estimates of $0.48 by $0.15. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. The business had revenue of $17.76 billion during the quarter, compared to analysts' expectations of $17.26 billion. During the same quarter in the prior year, the company earned $0.10 EPS. The firm's quarterly revenue was up 24.7% on a year-over-year basis. Analysts predict that Pfizer Inc. will post 2.95 EPS for the current year.
The company also recently disclosed a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be given a $0.43 dividend. The ex-dividend date of this dividend is Friday, January 24th. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.66%. This is a boost from Pfizer's previous quarterly dividend of $0.42. Pfizer's dividend payout ratio is currently 121.99%.
In other news, Director Ronald E. Blaylock bought 19,457 shares of the stock in a transaction on Thursday, February 13th. The stock was purchased at an average price of $25.65 per share, for a total transaction of $499,072.05. Following the acquisition, the director now owns 27,707 shares in the company, valued at approximately $710,684.55. This trade represents a 235.84 % increase in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Corporate insiders own 0.06% of the company's stock.
A number of large investors have recently added to or reduced their stakes in PFE. Swiss National Bank boosted its stake in shares of Pfizer by 0.6% during the 3rd quarter. Swiss National Bank now owns 16,819,712 shares of the biopharmaceutical company's stock worth $486,762,000 after buying an additional 100,900 shares during the last quarter. Charles Schwab Investment Management Inc. lifted its stake in Pfizer by 11.0% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 130,143,942 shares of the biopharmaceutical company's stock valued at $3,766,366,000 after purchasing an additional 12,864,343 shares during the last quarter. Empowered Funds LLC lifted its stake in Pfizer by 80.9% in the 3rd quarter. Empowered Funds LLC now owns 508,256 shares of the biopharmaceutical company's stock valued at $14,709,000 after purchasing an additional 227,349 shares during the last quarter. Addison Advisors LLC lifted its stake in Pfizer by 394.2% in the 3rd quarter. Addison Advisors LLC now owns 52,238 shares of the biopharmaceutical company's stock valued at $1,512,000 after purchasing an additional 41,668 shares during the last quarter. Finally, KBC Group NV lifted its stake in Pfizer by 26.0% in the 3rd quarter. KBC Group NV now owns 3,105,433 shares of the biopharmaceutical company's stock valued at $89,872,000 after purchasing an additional 639,985 shares during the last quarter. Institutional investors own 68.36% of the company's stock.
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Pfizer, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.
While Pfizer currently has a "Moderate Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.